Article Text

Download PDFPDF

Simvastatin reduced mortality and vascular events in diabetes mellitus

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with diabetes mellitus, does simvastatin reduce vascular events?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★★ Cardiology ★★★★★★☆ Endocrine ★★★★★★☆


Embedded ImageDesign:

randomised placebo controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded {participants, clinicians, data collectors, and outcome assessors}.*

Embedded ImageFollow up period:

mean 4.8 years of follow up.

Embedded ImageSetting:

{69 UK hospitals}.

Embedded ImagePatients:

5963 patients who were 40–80 years of age (mean age 62 y, 70% men); had non-fasting blood total cholesterol levels ⩾3.5 mmol/l; and had a medical history of diabetes mellitus, coronary heart disease, occlusive disease of non-coronary arteries, or treated hypertension (if also male and ⩾65 y of age). Exclusion criteria included indications or contraindications for statin therapy; myocardial infarction, stroke, or admission for angina in the previous 6 months; chronic liver disease; severe renal disease; and life threatening conditions other than vascular disease or diabetes.

Embedded ImageIntervention:

after a …

View Full Text

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd